Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 17/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.74 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.67 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954839 | 0.89 | PIK3CB (0.79) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2958328 | 0.87 | PIK3CB (0.76) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2954607 | 0.87 | PIK3CB (0.76) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL5898196 | 0.86 | PIK3CB (0.76) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2951414 | 0.86 | PIK3CB (0.74) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2957017 | 0.86 | PIK3CB (0.74) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2954920 | 0.86 | PIK3CB (0.74) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL374947 | 0.85 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL5897657 | 0.85 | PIK3CB (0.74) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2957174 | 0.85 | PIK3CB (0.74) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | claimed |
| EP-2409975-B1 | Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound | ZENYAKU KOGYO KK (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-8338414-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8227463-B2 | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2012-07-24 | — | — | US | disclosed |
| EP-1864665-B1 | IMMUNOSUPPRESSIVE AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-05-16 | — | — | EP | disclosed |
| EP-2409975-A1 | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-10-21 | — | — | US | disclosed |
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249063-A1 | AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2218718-A1 | AMORPHOUS FORM OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND MEDICINAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7750001-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-7307077-B2 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-11 | — | — | US | disclosed |
| EP-1389617-B1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040116421-A1 | Heterocyclic compound and antitumor agent containing the same as active ingredient | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1389617-A1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | PIK3CB 2354/4885PIK3CA 2655/4885PIK3CD 1584/4885 |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | PIK3CB 2354/4885PIK3CA 2655/4885PIK3CD 1584/4885 |
| US-20100249063-A1 | AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME | SBDS, ABCG2, SSRP1 | PIK3CB 4109/4885PIK3CA 3548/4885PIK3CD 4060/4885 |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | CBR3, HCCS, CBR1 | PIK3CB 3376/4885PIK3CA 2412/4885PIK3CD 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.